Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - potassium chloride, quantity: 1.5 g/l; sodium chloride, quantity: 1.8 g/l; glucose, quantity: 40 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride ( 0.15%) and sodium chloride (0.18 %) and glucose (4 %) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

baxter healthcare pty ltd - glucose, quantity: 40 g/l; potassium chloride, quantity: 2.24 g/l; sodium chloride, quantity: 1.8 g/l - injection, solution - excipient ingredients: water for injections - the potassium chloride (0.224%), sodium chloride (0.18%), and glucose (4%) intravenous infusion is indicated for replenishing fluid losses, as an energy source and for restoration or maintenance of sodium, potassium and chloride ions in the body fluids. it may be used as a vehicle of drug delivery where intravenous delivery is appropriate and the drug is compatible with this solution.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

wg critical care, llc - calcium gluconate monohydrate (unii: czn0mi5r31) (calcium cation - unii:2m83c4r6zb) - calcium gluconate in sodium chloride injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. limitations of use the safety of calcium gluconate in sodium chloride injection for long term use has not been established. calcium gluconate in sodium chloride injection is contraindicated in: •hyperca lcemia • neonates (28 days of age or younger) receiving ceftriaxone [see warnings and precautions (5.2)] risk summary limited available data with calcium gluconate injection use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. there are risks to the mother and the fetus associated with hypocalcemia in pregnancy [see clinical considerations] . the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respecti

Izraelis - anglų - Ministry of Health

teva israel ltd - glucose as monohydrate; sodium chloride - solution for infusion - glucose as monohydrate 5 %w/v; sodium chloride 0.45 %w/v - electrolytes with carbohydrates - sodium chloride 0.45 % and glucose 5 % soution for infusion baxter is indicated to provide electrolytes and calories and as a source of water for hydration

Izraelis - anglų - Ministry of Health

teva israel ltd - glucose as monohydrate; sodium chloride - solution for infusion - glucose as monohydrate 5 %w/v; sodium chloride 0.45 %w/v - electrolytes with carbohydrates - sodium chloride 0.45 % and glucose 5 % soution for infusion baxter is indicated to provide electrolytes and calories and as a source of water for hydration

Izraelis - anglų - Ministry of Health

teva israel ltd - glucose as monohydrate; sodium chloride - solution for infusion - glucose as monohydrate 5 %w/v; sodium chloride 0.9 %w/v - electrolytes with carbohydrates - sodium chloride 0.9 % and glucose 5 % solution for infusion baxter is indicated as a source of water, electrolytes and/or calories.

Izraelis - anglų - Ministry of Health

teva israel ltd - glucose as monohydrate; sodium chloride - solution for infusion - glucose as monohydrate 5 %w/v; sodium chloride 0.9 %w/v - electrolytes with carbohydrates - sodium chloride 0.9 % and glucose 5 % solution for infusion baxter is indicated as a source of water, electrolytes and/or calories.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

teva pharmaceuticals usa, inc. - polyethylene glycol 3350 (unii: g2m7p15e5p) (polyethylene glycol 3350 - unii:g2m7p15e5p), sodium chloride (unii: 451w47iq8x) (chloride ion - unii:q32zn48698), sodium sulfate (unii: 0ypr65r21j) (sodium sulfate anhydrous - unii:36kcs0r750), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152) - peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults. peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution is contraindicated in the following conditions: -   gastrointestinal (gi) obstruction [see warnings and precautions (5.6)] -   bowel perforation [see warnings and precautions (5.6)] -   gastric retention -   ileus -   toxic colitis or toxic megacolon -   hypersensitivity to any ingredient in peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution [see warnings and precautions (5.10)] risk summary there are no available data on peg-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate, and ascorbic acid for oral solution in pregnant women to inform a drug-associated risk for adverse developmental

Kanada - anglų - Health Canada

baxter corporation - sodium chloride - solution - 20% - sodium chloride 20% - replacement preparations

Izraelis - anglų - Ministry of Health

teva medical marketing ltd. - calcium chloride dihydrate; potassium chloride; sodium chloride; sodium lactate - solution for infusion - sodium lactate 0.32 %w/v; calcium chloride dihydrate 0.027 %w/v; potassium chloride 0.04 %w/v; sodium chloride 0.6 %w/v - calcium chloride - calcium chloride - source of water and electrolytes. regulation or maintenance of metabolic acidosis ( except lactic acidosis).